Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 12/2023

23-10-2023 | Herpes Virus | Brief Report

Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies

Authors: Martin Martinot, Simon Gravier, Mahsa Mohseni-Zadeh, Nicole Fabien, Jean-Laurent Casanova, Anne Puel, David Goncalves

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2023

Login to get access

Abstract

Herpes simplex virus type 2 (HSV-2) is a common cause of infection, which is usually self-limited and asymptomatic. A 71-year-old patient with HSV-2 primo-infection developed acute hepatitis and secondary hemophagocytic lymphohistiocytosis. The patient had high levels of autoantibodies against type I interferon (IFN) (> 1000 ng/mL), neutralizing high concentration (10 ng/mL) of both IFN-α and IFN-ω but not IFN-β. Anti-IFN-I auto-antibodies are rarely observed in healthy individuals; however, their prevalence increases in individuals over 70 years of age and have been identified as a cause of some severe viral diseases, including critical COVID-19. Considering the function of IFN-I in innate immunity, the pathological role of these autoantibodies in severe viral diseases following primo-infections in elderly patient appears crucial.
Literature
1.
go back to reference Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM (2015) Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE 10(1):e114989CrossRefPubMedPubMedCentral Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM (2015) Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS ONE 10(1):e114989CrossRefPubMedPubMedCentral
2.
go back to reference Lai VWY, Meher-Homji Z, Liu F, Sasadeusz J (2020) Primary herpes simplex virus type 2 hepatitis diagnosed during laparoscopy. Lancet 396(10265):e90CrossRefPubMed Lai VWY, Meher-Homji Z, Liu F, Sasadeusz J (2020) Primary herpes simplex virus type 2 hepatitis diagnosed during laparoscopy. Lancet 396(10265):e90CrossRefPubMed
3.
go back to reference Czartoski T, Liu C, Koelle DM, Schmechel S, Kalus A, Wald A (2006) Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J Clin Microbiol 44(4):1584–1586CrossRefPubMedPubMedCentral Czartoski T, Liu C, Koelle DM, Schmechel S, Kalus A, Wald A (2006) Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J Clin Microbiol 44(4):1584–1586CrossRefPubMedPubMedCentral
4.
go back to reference Yamamoto T, Kenzaka T, Matsumoto M, Nishio R, Kawasaki S, Akita H (2018) A case report of myocarditis combined with hepatitis caused by herpes simplex virus. BMC Cardiovasc Disord 18(1):134CrossRefPubMedPubMedCentral Yamamoto T, Kenzaka T, Matsumoto M, Nishio R, Kawasaki S, Akita H (2018) A case report of myocarditis combined with hepatitis caused by herpes simplex virus. BMC Cardiovasc Disord 18(1):134CrossRefPubMedPubMedCentral
5.
go back to reference Sonpar A, Brown K, Chen J et al (2018) Dual infection in pregnancy: disseminated mycoplasma hominis and necrotizing herpes simplex 2 hepatitis. Int J Infect Dis 71:1–3CrossRefPubMed Sonpar A, Brown K, Chen J et al (2018) Dual infection in pregnancy: disseminated mycoplasma hominis and necrotizing herpes simplex 2 hepatitis. Int J Infect Dis 71:1–3CrossRefPubMed
6.
go back to reference Yuasa M, Ishiwata K, Sugio T et al (2014) Herpes simplex virus type 2 fulminant hepatitis after umbilical cord blood transplantation for acute myeloid leukemia. Rinsho Ketsueki 55(6):682–686PubMed Yuasa M, Ishiwata K, Sugio T et al (2014) Herpes simplex virus type 2 fulminant hepatitis after umbilical cord blood transplantation for acute myeloid leukemia. Rinsho Ketsueki 55(6):682–686PubMed
7.
go back to reference Ganner A, Lee YM, Busche C et al (2007) Successful liver transplantation in a kidney and pancreas allograft recipient with fulminant herpes simplex virus type 2 hepatitis. Nephrol Dial Transplant 22(11):3334–3337CrossRefPubMed Ganner A, Lee YM, Busche C et al (2007) Successful liver transplantation in a kidney and pancreas allograft recipient with fulminant herpes simplex virus type 2 hepatitis. Nephrol Dial Transplant 22(11):3334–3337CrossRefPubMed
8.
go back to reference Ichai P, Roque Afonso AM, Sebagh M et al (2005) Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl 11(12):1550–1555CrossRefPubMed Ichai P, Roque Afonso AM, Sebagh M et al (2005) Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl 11(12):1550–1555CrossRefPubMed
9.
go back to reference Ambrosioni J, Kaiser L, Giostra E et al (2012) Herpes simplex virus load to monitor antiviral treatment after liver transplantation for acute herpetic hepatitis. Antivir Ther 17(2):401–404CrossRefPubMed Ambrosioni J, Kaiser L, Giostra E et al (2012) Herpes simplex virus load to monitor antiviral treatment after liver transplantation for acute herpetic hepatitis. Antivir Ther 17(2):401–404CrossRefPubMed
10.
go back to reference Srinivasan D, Kaul CM, Buttar AB, Nottingham FI, Greene JB (2021) Disseminated herpes simplex virus-2 (HSV-2) as a cause of viral hepatitis in an immunocompetent host. Am J Case Rep 22:e932474CrossRefPubMedPubMedCentral Srinivasan D, Kaul CM, Buttar AB, Nottingham FI, Greene JB (2021) Disseminated herpes simplex virus-2 (HSV-2) as a cause of viral hepatitis in an immunocompetent host. Am J Case Rep 22:e932474CrossRefPubMedPubMedCentral
11.
go back to reference Chavez SM, Poniachik JM, Urzua AM et al (2021) Acute liver failure due to herpes simplex virus: diagnostic clues and potential role of plasmapheresis: a case report. Medicine 100(35):e27139CrossRefPubMedPubMedCentral Chavez SM, Poniachik JM, Urzua AM et al (2021) Acute liver failure due to herpes simplex virus: diagnostic clues and potential role of plasmapheresis: a case report. Medicine 100(35):e27139CrossRefPubMedPubMedCentral
13.
go back to reference Tognarelli EI, Palomino TF, Corrales N, Bueno SM, Kalergis AM, Gonzalez PA (2019) Herpes simplex virus evasion of early host antiviral responses. Front Cell Infect Microbiol 9:127CrossRefPubMedPubMedCentral Tognarelli EI, Palomino TF, Corrales N, Bueno SM, Kalergis AM, Gonzalez PA (2019) Herpes simplex virus evasion of early host antiviral responses. Front Cell Infect Microbiol 9:127CrossRefPubMedPubMedCentral
14.
go back to reference Zhang Q, Bastard P, Liu Z et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370:eabd4570 Zhang Q, Bastard P, Liu Z et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370:eabd4570
15.
go back to reference Matuozzo D, Talouarn E, Marchal A et al (2023) Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med 15(1):22CrossRefPubMedPubMedCentral Matuozzo D, Talouarn E, Marchal A et al (2023) Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med 15(1):22CrossRefPubMedPubMedCentral
16.
go back to reference Asano T, Boisson B, Onodi F et al (2021) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 6:eabl4348 Asano T, Boisson B, Onodi F et al (2021) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci Immunol 6:eabl4348
17.
go back to reference Bastard P, Gervais A, Le Voyer T et al (2021) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6:eabl4340 Bastard P, Gervais A, Le Voyer T et al (2021) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 6:eabl4340
18.
go back to reference Manry J, Bastard P, Gervais A et al (2022) The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A 119(21):e2200413119CrossRefPubMedPubMedCentral Manry J, Bastard P, Gervais A et al (2022) The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Natl Acad Sci U S A 119(21):e2200413119CrossRefPubMedPubMedCentral
19.
go back to reference Wang X, Tang Q, Li H et al (2023) Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis. Int J Infect Dis 130:147–152CrossRefPubMedPubMedCentral Wang X, Tang Q, Li H et al (2023) Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis. Int J Infect Dis 130:147–152CrossRefPubMedPubMedCentral
20.
go back to reference Goncalves D, Mezidi M, Bastard P et al (2021) Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunology 10(8):e1327CrossRefPubMedPubMedCentral Goncalves D, Mezidi M, Bastard P et al (2021) Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin Transl Immunology 10(8):e1327CrossRefPubMedPubMedCentral
21.
go back to reference Jongbloed EM, Hermans MAW, Wabbijn M, van Kampen JJA, van Laar JAM (2020) HLH caused by an HSV-2 infection: a case report and review of the literature. Neth J Med 78(5):282–285PubMed Jongbloed EM, Hermans MAW, Wabbijn M, van Kampen JJA, van Laar JAM (2020) HLH caused by an HSV-2 infection: a case report and review of the literature. Neth J Med 78(5):282–285PubMed
22.
go back to reference Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eabd4585 Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eabd4585
23.
go back to reference Zhang Q, Pizzorno A, Miorin L et al (2022) Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med 219(11):e20220514 Zhang Q, Pizzorno A, Miorin L et al (2022) Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med 219(11):e20220514
24.
go back to reference Pozzetto B, Mogensen KE, Tovey MG, Gresser I (1984) Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis 150(5):707–713CrossRefPubMed Pozzetto B, Mogensen KE, Tovey MG, Gresser I (1984) Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis 150(5):707–713CrossRefPubMed
25.
go back to reference Ansari R, Rosen LB, Lisco A et al (2021) Primary and acquired immunodeficiencies associated with severe varicella-zoster virus infections. Clin Infect Dis 73(9):e2705–e2712CrossRefPubMed Ansari R, Rosen LB, Lisco A et al (2021) Primary and acquired immunodeficiencies associated with severe varicella-zoster virus infections. Clin Infect Dis 73(9):e2705–e2712CrossRefPubMed
26.
go back to reference Gervais A, Rovida F, Avanzini MA et al (2023) Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. J Exp Med 220(9):e20230661 Gervais A, Rovida F, Avanzini MA et al (2023) Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. J Exp Med 220(9):e20230661
27.
go back to reference Alotaibi F, Alharbi NK, Rosen LB et al (2023) Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. Influenza Other Respir Viruses 17(3):e13116CrossRefPubMedPubMedCentral Alotaibi F, Alharbi NK, Rosen LB et al (2023) Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. Influenza Other Respir Viruses 17(3):e13116CrossRefPubMedPubMedCentral
28.
go back to reference Bastard P, Michailidis E, Hoffmann HH et al (2021) Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med 218(4):e20202486 Bastard P, Michailidis E, Hoffmann HH et al (2021) Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med 218(4):e20202486
29.
go back to reference Busnadiego I, Abela IA, Frey PM et al (2022) Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol 20(7):e3001709CrossRefPubMedPubMedCentral Busnadiego I, Abela IA, Frey PM et al (2022) Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol 20(7):e3001709CrossRefPubMedPubMedCentral
30.
go back to reference Mathian A, Breillat P, Dorgham K et al (2022) Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. Ann Rheum Dis 81(12):1695–1703CrossRefPubMed Mathian A, Breillat P, Dorgham K et al (2022) Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. Ann Rheum Dis 81(12):1695–1703CrossRefPubMed
31.
go back to reference Hetemaki I, Laakso S, Valimaa H et al (2021) Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin Immunol 231:108851CrossRefPubMedPubMedCentral Hetemaki I, Laakso S, Valimaa H et al (2021) Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections. Clin Immunol 231:108851CrossRefPubMedPubMedCentral
32.
go back to reference Bastard P, Vazquez S, Liu J et al (2022) Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol 0:eabp8966 Bastard P, Vazquez S, Liu J et al (2022) Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci Immunol 0:eabp8966
Metadata
Title
Severe acute herpes virus type 2 primo-infection and its association with anti-type 1 interferon autoantibodies
Authors
Martin Martinot
Simon Gravier
Mahsa Mohseni-Zadeh
Nicole Fabien
Jean-Laurent Casanova
Anne Puel
David Goncalves
Publication date
23-10-2023
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2023
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-023-04688-5

Other articles of this Issue 12/2023

European Journal of Clinical Microbiology & Infectious Diseases 12/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.